61 results about "PAPILLOMAVIRUS HUMAN" patented technology

The present application relates to the field of molecular biology, in particular to a primer probe composition, kit and detection method for 23 human papilloma virus genotyping detection, wherein the hydrolysis probe and molecular beacon probe are respectively designed in two different regions of HPV gene sequence E6 and L1, and the fluorescence collection point in the amplification stage is set in the high-temperature denaturation stage, so that the detection in the amplification stage and the melting curve stage is independent and does not interfere with each other, thereby realizing the combined use of real-time fluorescent PCR amplification detection technology and melting curve technology; the technology improves the single-well detection target flux of fluorescent PCR analysis technology, reduces the detection cost, and provides a more optimal detection method for HPV multiplex fluorescent PCR genotyping detection.

The invention discloses a human papilloma virus mRNA (messenger ribonucleic acid) detection kit for auxiliary diagnosis of cervical cancer patients. The human papilloma virus mRNA detection kit comprises a nucleic acid probe group and a series of nucleic acid probes AMP1-AMP5, wherein the nucleic acid probe group is used for being combined with a human papilloma virus mRNA target, and the nucleic acid probes AMP1-AMP5 are used for signal amplification. The human papilloma virus mRNA detection kit provided by the invention can assist pathologists in identifying and diagnosing cervical cancer patients, and provides a basis for clinicians to formulate a therapeutic schedule.

The application discloses a marker group for cervical cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-42.The marker group constructed by the application has more excellent sensitivity and specificity when used for auxiliary diagnosis and early screening of cervical cancer.The auxiliary diagnosis result is superior to the efficiency (sensitivity 81.1%, specificity 78.9%) of combined detection of serum CEA, SCC-Ag and CA125 in early diagnosis of cervical cancer;the diagnostic sensitivity and specificity of serum cf-DNA are 72.2% and 81.7% respectively.The early screening result is also superior to the internationally recognized cervical cancer screening method, i.e., combined screening of cytological detection (TCT) and human papilloma virus (HPV) virology detection.

The invention provides a fabric cleaning agent with an anti-HPV effect and a preparation method thereof, and relates to the technical field of cleaning agents. According to the Gemini type quaternary ammonium salt surfactant composition disclosed by the invention, through the effects of the Gemini type quaternary ammonium salt surfactants with two specific structures, high synergy of washing and disinfecting functions is realized, excellent dirt-removing power can be achieved only by virtue of an optimized and compounded surfactant system, and biological enzymes which are easy to inactivate and difficult to stabilize do not need to be introduced; in a high-content surfactant system and in a weak acid environment, the compound still has an efficient and reliable antiviral effect on the human papilloma virus, and meets the dual requirements of public health and personal care; and the formula is mild and weakly acidic and fits the physiological environment of the skin, so that the use experience and the effect exertion are favorably improved.

Immunogenic compositions and methods of use thereof, for eliciting an immune response against one or more virally driven cancers are described. The compositions typically include one or more viral antigens expressed in the virally driven cancers, or a nucleic acid encoding the same, and optionally one or more adjuvants. Preferably, the compositions include nucleic acids (e.g., mRNA) encoding one or more viral antigens. Exemplary antigens include those derived from a truncated form of the viral Large T Antigen (LTA) or Small T Antigen (STA) of Merkel Cell Polyomavirus (MCPyV), or E2, E5, or E6 proteins of HPV. Pharmaceutical compositions and dosages including one or more of the compositions and an excipient, and methods of immunizing subjects and priming and engineer T cells for use in adoptive therapy are also provided.

The application provides a primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR and application thereof, and belongs to the technical field of human papilloma virus detection products. The primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR comprises a multi-target primer probe combination for detecting HPV16, and a multi-target primer probe combination for detecting HPV18, wherein the nucleotide sequence of the primer probe combination for detecting HPV16 is shown in SEQ ID NO. 1-27, and the nucleotide sequence of the primer probe combination for detecting HPV18 is shown in SEQ ID NO. 28-54. The primer probe combination has high sensitivity and low detection limit, can accurately detect HPV16 and HPV18 with high specificity and low cost, accurately capture trace ctDNA in early cervical cancer patient samples, significantly improve the early diagnosis rate, and effectively avoid the missed detection risk of single detection.

The present application provides antibodies or antigen-binding fragments thereof that target human papilloma virus. The invention also relates to application of the antibody or the antigen binding fragment thereof in treatment, prevention and / or diagnosis of human papilloma virus infection or diseases caused by human papilloma virus infection.

The invention relates to the technical field of molecular biology, in particular to a super-quenching probe and application thereof. According to the super-quenching probe provided by the invention, a quenching group ZEN is inserted into the 3-4 base sites in the middle of a nucleic acid sequence, so that the background of the MGB type probe is remarkably reduced, the signal-to-noise ratio is increased, and the detection sensitivity is higher in the actual qPCR application process. Compared with a common probe, when the super-quenching probe is applied to human papilloma virus detection, the super-quenching probe can show more excellent detection accuracy and sensitivity under the sample concentration of 1000 times.

The utility model belongs to the field of high-risk human papilloma virus detection, in particular relates to a disposable reagent feeding tube, and aims to solve the problems that when the conventional disposable reagent feeding tube is used, the dosage cannot be well controlled, so that the reagent quantities in multiple inspection processes are different, part of needle tubes with quantitative functions are higher in cost. According to the technical scheme, the reagent adding pipe comprises a reagent measuring cup and a reagent adding pipe body, the reagent adding pipe body and the reagent measuring cup are used in a matched mode, a piston block is connected into the reagent adding pipe body in a sliding mode, a piston rod is fixedly connected to the top of the piston block, and a second protruding plate is fixedly connected to the top of the piston rod. The second protruding plate is pulled to drive the piston rod and the piston block to move upwards, the reagent in the reagent measuring cup can be quantitatively extracted, the disposable design is adopted, cleaning and disinfection are not needed, the workload and cost are reduced, the reagent amount can be accurately controlled, the operation process is simplified, and therefore the detection efficiency can be greatly improved.

Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

The present disclosure relates to compositions, kits, systems, and methods for detecting the presence or absence of human papillomavirus 16 (HPV16) or HPV18 nucleic acid (e.g., cell-free DNA) in a sample from a subject. In particular embodiments, a sample is contacted with at least one set of oligonucleotide having a forward primer, reverse primer, and a detectable labeled probe (e.g., for detecting PCR generated amplicons). In certain embodiments, the amount of HPV16 or HPV18 in the sample is quantitated (e.g., quantitative PCR is employed).

The present invention relates to a combination of markers for detecting human papillomavirus (HPV) in a cervical sample, wherein said combination of markers comprises a first marker selected from MUC5B and / or TFF3 for verifying the reliability of the cervical sample, wherein the expression of the first marker indicates that the cervical sample comprises cells from the cervical transition zone and / or endocervical canal; and a second marker for detecting HPV. Further, the present invention relates to a method for verifying the reliability of a biological sample, as well as a method for detecting HPV in a biological sample, based on the analysis of the one or more markers selected from MUC5B and / or TFF3. Also provided is the use of the novel markers of the invention for verifying the reliability of a biological sample. Furthermore, provided are methods for screening of sexually transmitted infections (STI) and of dysplastic / neoplastic lesions in a biological sample. The present invention also provides a kit of parts for the above-mentioned methods.

Disclosed in the present invention are a self-replicating messenger ribonucleic acid (mRNA) sequence and a use thereof in preparation of an anti-human papillomavirus (HPV) tumor drug. A self-replicating mRNA base comprises a sequence as shown in at least one of SEQ ID NO: 8, SEQ ID NO: 13, and SEQ ID NO: 15. In the present invention, mutation and tandem design is carried out on the basis of E6 and E7 proteins, thereby improving the immunogenicity of E6 and E7 proteins expressed by an mRNA, and overcoming the pain point problem in the traditional technology of E6 and E7 proteins for vaccines being difficult to be effectively recognized by a human immune system.

The application relates to a primer probe composition and application for human papilloma virus nucleic acid typing detection. The primer probe composition comprises one universal label primer and 28 groups of primer probe groups respectively used for detecting 28 human papilloma virus nucleic acid types; wherein each group of the primer probe group comprises one upstream primer, one downstream primer and one probe, and the 5' ends of the upstream primer and the downstream primer are marked with the universal label primer, and the base sequence of the universal label primer is shown as SEQ ID NO: 59. The primer probe composition or kit can realize single-tube and simultaneous detection of 28 HPV subtypes, has high detection accuracy, good sensitivity and specificity, and the whole detection process can be automatically realized by using a full-automatic device.

This disclosure provides a method for evaluating the prognosis of a head and neck cancer patient. The head and neck cancer may be human papillomavirus positive (HPV+) and originate in the upper aerodigestive tract (e.g. oropharynx, nasopharynx, nasal cavity, sinus, or hypopharynx). In addition, the disclosure provides a method for predicting a response of a head and neck cancer patient to a selected treatment. The disclosure also provides a method for generating an improved head and neck cancer biomarker signature for patient prognosis and uses thereof.

The invention discloses a marker group for screening and diagnosing cervical cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO.1-42. The invention further discloses a method for detecting the biomarker group. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of cervical cancer. The auxiliary diagnosis result is superior to the efficacy (the sensitivity is 81.1%, and the specificity is 78.9%) of serum CEA, SCC-Ag and CA125 combined detection in early stage cervical cancer diagnosis; the diagnostic sensitivity and specificity of the serum cf-DNA are 72.2% and 81.7% respectively. The early screening result is better than that of the current internationally recognized cervical cancer screening means, namely a combined screening mode of cytological detection (TCT) and human papilloma virus (HPV) virology detection.

Described herein are compositions and methods of using the same. The compositions can include a first nucleic acid encoding for an HPV E6 peptide or a variant or fragment thereof; a second nucleic acid encoding for an HPV E7 peptide or a variant or fragment thereof; and a third nucleic acid encoding a subdomain of the SARS-CoV-2 spike protein.

The application provides an electrochemical DNA biosensor for detecting human papilloma virus 16 subtype (HPV-16), which utilizes base complementary pairing to specifically combine different single-stranded DNAs, and when HPV-16 is added, a DNA strand displacement reaction can be triggered to increase the electrochemical impedance (EIS) response. Within a certain range, as the concentration of HPV-16 increases, the EIS response signal also increases. The electrochemical DNA biosensor provided by the application has the advantages of simple preparation process, convenient operation, low detection limit of 33.8 pM and fast detection speed.

The application discloses an E2 fusion protein, a coding gene thereof and application of the E2 fusion protein. The E2 fusion protein is fused by an E2 protein and a label; the amino acid sequence of the E2 protein is shown as positions 1 to 365 from the N-terminal end in SEQ ID NO:1. Experiments prove that the E2 protein has a helicase activity, and an anti-human papillomavirus drug, a podophyllotoxin, can inhibit the helicase activity of the E2 protein. Therefore, the E2 protein is a target of the action of the podophyllotoxin, and the E2 protein can also be used as a target for screening the anti-human papillomavirus drug. The application has important application value in the process of screening the anti-human papillomavirus drug.

Provided herein are varicella-zoster virus vaccine, human papilloma virus vaccine, and rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and treatment of cancer.

To provide a combination for use in the treatment of HPV-positive cancer.SOLUTION: The present invention relates to a combination of a) a poxviral vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immune-stimulatory cytokine, and b) anti-PD L1 antibodies or antigen binding fragments thereof, for use in the treatment of HPV-positive cancers, wherein a first administration of said poxviral vector is performed 5 to 10 days before a first administration of said anti-PD L1 antibodies, and wherein subsequent administrations of said poxviral and anti-PD L1 antibodies are performed.SELECTED DRAWING: None

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and / or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

The present application provides antibodies or antigen-binding fragments thereof that target human papilloma virus. The invention also relates to application of the antibody or the antigen binding fragment thereof in treatment, prevention and / or diagnosis of human papilloma virus infection or diseases caused by human papilloma virus infection.

The present invention relates to compounds of formula (I), especially the use thereof as degraders of Human Papilloma Virus E7 proteins.

The utility model discloses a multi-parting detection kit for human papilloma virus detection, which comprises a kit body, an opening is arranged on the upper side of the kit body, a kit cover is hinged on one side of the opening, four buffer components are mounted at the bottom of the kit body, parting support plates are mounted among the four buffer components, and the parting support plates are hinged on the upper side of the kit body. A parting inserting plate is installed on the upper side of the parting supporting plate, and a plurality of clamping assemblies are arranged on the parting inserting plate in an array mode. Wherein the clamping assembly comprises an inserting groove located in a parting inserting plate, a test tube is inserted into the inserting groove till the bottom end of the test tube abuts against the interior of a concave groove, a pressing ring is screwed, the pressing ring drives an inner threaded barrel to spirally move downwards along an outer threaded barrel, the inner wall of the pressing ring extrudes inclined faces of triangular plates, and the outer wall of the test tube is jointly clamped by the multiple triangular plates; the device is simple in structure, easy to operate and control, suitable for test tubes with different diameters, high in universality and capable of ensuring that the test tubes cannot loosen or shift in the shaking or transporting process.

This invention discloses an antibody against human papillomavirus E1 protein or a kit thereof and related applications, relating to the field of immunoassay. The antibody comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:14 and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:15. It can specifically bind to HPV16 and / or 18 E1 protein and has advantages such as high detection sensitivity, strong specificity, high accuracy and good repeatability.

The invention provides a composition, a kit, an application for detecting human papilloma virus in a sample, a method for detecting the existence or type of the human papilloma virus in the sample, a model construction method for predicting the recombinase polymerase amplification reaction efficiency of a virus template chain, and a prediction method for the recombinase polymerase amplification reaction efficiency. The present invention relates to a composition comprising: a number of different bait oligonucleotides wherein the number of different bait oligonucleotides are configured to hybridize to a number of DNA molecules that are at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of a sequence derived from any one or number of SEQ ID NO: 91-100, and wherein the number of DNA molecules is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of a sequence derived from any one or number of SEQ ID NO: 91-100; the composition can be used for detecting the human papilloma virus with the genotype.

The present disclosure provides, inter alia, a vaccine composition comprising a squalene nanoemulsion (SNE) adjuvant and at least one type of virus-like particle (VLP) of human papilloma virus (HPV) selected from the following HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

The application discloses a quality control product for human papillomavirus molecular detection and a preparation method thereof, and belongs to the technical field of biological products. After synthesizing 25 types of HPV full genomes of high-risk types (HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, HPV82) and low-risk types (HPV6, HPV11, HPV42, HPV43, HPV44, HPV81, HPV83), the HPV full genomes are connected into a pcDNA3.1(+) skeleton vector system, the HPV full genomes are integrated into the genome of a human ovarian cancer cell line ovcar3 respectively, and 25 strains of human ovarian cancer cell lines stably integrating the HPV full genomes are obtained. The new quality control product or kit of various types of simulated clinical samples such as genomic DNA, cell precipitate and cell suspension can be prepared and is suitable for various detection platforms. The human cell line quality control product stably integrating the full-length genomes of the 25 HPV types can more accurately determine the viral load and control the whole process of HPV detection.

This invention provides a graduated and squeezeable container for human papillomavirus (HPV) preservation solution, comprising a tube body and a cap at the top of the tube body. The tube body has graduations on its side wall and is a flexible tube made of LDPE. A silicone mold with multiple 0.2mm diameter mesh openings is located at the top inlet of the tube body. The cap is an inverted cone shape and is fastened to the top inlet of the tube body. A 0.2cm diameter sample dispensing port is located at the top of the cap. This container has a simple structure and is easy to operate. Squeezing effectively removes impurities and mucus, extracting effective nucleic acids, effectively avoiding sample contamination, improving work efficiency, avoiding wear and tear on the pipette tip due to re-examination, and reducing consumable costs.